Nabholtz Jean-Marc, Gligorov Joseph
Breast Cancer Research Institute, La Prandie, 24290 Valojoulx, France.
Expert Rev Anticancer Ther. 2005 Aug;5(4):613-33. doi: 10.1586/14737140.5.4.613.
It has become clear over the past 10 years that docetaxel, a semisynthetic taxoid antineoplastic agent, is among the most promising compounds to have been developed in the 1990s for the treatment of breast cancer. Data indicate that this drug became standard therapy in the treatment of patients with metastatic disease who have failed anthracycline treatment, and secondarily showed very encouraging results in the first-line metastatic setting either in monochemotherapy or when docetaxel was combined with an anthracycline. More recently, docetaxel also became one of the standard therapies in the adjuvant and neoadjuvant settings, and a promising partner for novel biologic therapies. Current research is further exploring the effect of docetaxel on outcome of early breast cancer in order to fully determine the extent that this chemotherapeutic agent will change the natural history of breast cancer.
在过去10年中已明确，多西他赛，一种半合成紫杉烷类抗肿瘤药，是20世纪90年代开发的用于治疗乳腺癌的最有前景的化合物之一。数据表明，该药物已成为蒽环类治疗失败的转移性疾病患者治疗的标准疗法，其次在一线转移性治疗中，无论是单药化疗还是多西他赛与蒽环类联合使用，均显示出非常令人鼓舞的结果。最近，多西他赛也成为辅助和新辅助治疗的标准疗法之一，并且是新型生物疗法的有前景的搭档。目前的研究正在进一步探索多西他赛对早期乳腺癌结局的影响，以便充分确定这种化疗药物将改变乳腺癌自然病程的程度。
